MX2007010484A - Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2. - Google Patents

Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.

Info

Publication number
MX2007010484A
MX2007010484A MX2007010484A MX2007010484A MX2007010484A MX 2007010484 A MX2007010484 A MX 2007010484A MX 2007010484 A MX2007010484 A MX 2007010484A MX 2007010484 A MX2007010484 A MX 2007010484A MX 2007010484 A MX2007010484 A MX 2007010484A
Authority
MX
Mexico
Prior art keywords
molecules
methods
same
associated diseases
mcp
Prior art date
Application number
MX2007010484A
Other languages
English (en)
Spanish (es)
Inventor
Nathan Karin
Gizi Wildbaum
Yaniv Zohar
Liat Izhak
Uri Weinberg
Original Assignee
Rappaport Family Inst For Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rappaport Family Inst For Res filed Critical Rappaport Family Inst For Res
Publication of MX2007010484A publication Critical patent/MX2007010484A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2007010484A 2005-04-15 2006-04-10 Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2. MX2007010484A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67147605P 2005-04-15 2005-04-15
PCT/IL2006/000454 WO2006109301A2 (en) 2005-04-15 2006-04-10 Molecules and methods of using same for treating mcp-1/ccr2 associated diseases

Publications (1)

Publication Number Publication Date
MX2007010484A true MX2007010484A (es) 2007-10-15

Family

ID=36688002

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007010484A MX2007010484A (es) 2005-04-15 2006-04-10 Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.

Country Status (11)

Country Link
US (1) US8388962B2 (enExample)
EP (1) EP1871798B1 (enExample)
JP (1) JP2008535909A (enExample)
CN (1) CN101160323A (enExample)
AT (1) ATE445644T1 (enExample)
AU (1) AU2006233927A1 (enExample)
CA (1) CA2597789A1 (enExample)
DE (1) DE602006009786D1 (enExample)
ES (1) ES2333358T3 (enExample)
MX (1) MX2007010484A (enExample)
WO (1) WO2006109301A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007010484A (es) 2005-04-15 2007-10-15 Rappaport Family Inst For Res Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
EP1989216A4 (en) * 2006-03-01 2010-03-31 Univ Michigan DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
EP2193805A4 (en) 2007-08-24 2013-09-04 Univ Keio IMMUNOSUPPRESSION DETOXIFICANT WITH TUMOR CELLS AND THIS USE ANTITUMOROUS AGENT
CN102370981B (zh) * 2010-08-11 2014-07-16 中国科学院上海生命科学研究院 防治神经退行性疾病的试剂和方法
HK1219891A1 (zh) * 2013-08-06 2017-04-21 国立大学法人九州大学 有机酸聚合物作为有效组分的、预防或抑制癌细胞生存的药物
NO2776305T3 (enExample) 2014-04-23 2018-01-27
CN107362353A (zh) * 2016-05-11 2017-11-21 上海长海医院 一种去势抵抗的前列腺癌相关的药物靶点及其应用
KR102308102B1 (ko) * 2018-05-18 2021-10-07 가톨릭대학교 산학협력단 Ccr2를 유효성분으로 포함하는 골질환의 예방 또는 치료용 조성물
US20220409698A1 (en) * 2019-11-15 2022-12-29 The Catholic University Of Korea Industry-Academic Cooperation Foundation Composition for preventing or treating bone diseases comprising ccr2
KR102308099B1 (ko) * 2019-11-15 2021-10-01 가톨릭대학교 산학협력단 Soluble CCR2 발현 유도된 줄기세포를 유효성분으로 포함하는 골질환의 예방 또는 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1679395A (en) * 1994-01-13 1995-08-01 Regents Of The University Of California, The Mammalian monocyte chemoattractant protein receptors
SE9600820D0 (sv) * 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
US6528625B1 (en) 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
AU2001243145A1 (en) 2000-02-09 2001-08-20 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
FR2828102B1 (fr) * 2001-03-28 2004-07-09 Ifc Sa Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
ATE364050T1 (de) 2003-07-24 2007-06-15 Amgen Inc Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak- rezeptors betreffen
IL157398A0 (en) 2003-08-14 2004-02-19 Hadasit Med Res Service Pharmaceutical compositions comprising ccr5 antagonists
GB2423472A (en) 2003-12-11 2006-08-30 Univ Yale Methods and compositions relating to ccr5 antagonist,ifn-&gammed;and il-13 induced inflammation
US20050215543A1 (en) 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
MX2007010484A (es) 2005-04-15 2007-10-15 Rappaport Family Inst For Res Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.

Also Published As

Publication number Publication date
DE602006009786D1 (de) 2009-11-26
JP2008535909A (ja) 2008-09-04
EP1871798B1 (en) 2009-10-14
ES2333358T3 (es) 2010-02-19
CA2597789A1 (en) 2006-10-19
US8388962B2 (en) 2013-03-05
WO2006109301A3 (en) 2006-12-07
US20110033521A1 (en) 2011-02-10
ATE445644T1 (de) 2009-10-15
AU2006233927A1 (en) 2006-10-19
CN101160323A (zh) 2008-04-09
WO2006109301A2 (en) 2006-10-19
EP1871798A2 (en) 2008-01-02

Similar Documents

Publication Publication Date Title
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
IL258880A (en) Diarylhydantoin compounds
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
MY160041A (en) Compositions and methods for treating parasitic infections
SG155947A1 (en) Compositions and methods for the diagnosis and treatment of tumor
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
EP1954274A4 (en) SUBSTITUTED QUINOLONES AND METHODS OF USE
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
IL181629A0 (en) Compositions and methods for the diagnosis and tretment of tumor
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
PH12014500053A1 (en) Proteasome inhibitors
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
SG161318A1 (en) Heterocyclic inhibitors of mek and methods of use thereof
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MY147247A (en) Organic compounds and their uses
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
TW200716088A (en) Formulations and methods for treating amyloidosis
TW200716561A (en) P38 inhibitors and methods of use thereof
GB0508988D0 (en) Organic compounds
IL206133A0 (en) Molecules and methods of using same for treating mcp-1/ccr2 associated diseases

Legal Events

Date Code Title Description
FG Grant or registration